Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled ‘A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator’s Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)’. This study aims to evaluate the safety and efficacy of odronextamab compared to rituximab combined with chemotherapy in patients with follicular lymphoma, a type of non-Hodgkin lymphoma. The significance of this study lies in its potential to offer a new treatment option for this condition.
The intervention being tested is odronextamab, an experimental bispecific antibody designed to target CD20 and CD3 proteins. Its purpose is to provide a potentially more effective treatment for follicular lymphoma compared to the current standard of care, which includes rituximab and chemotherapy.
The study design is interventional and randomized, with a parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is treatment. The study consists of two parts: Part 1 assesses the safety of odronextamab, while Part 2 compares its efficacy against standard treatments.
The study began on December 12, 2023, with an estimated primary completion date in June 2025. The last update was submitted on June 24, 2025. These dates are crucial for tracking the progress and anticipated results of the study.
The market implications of this study could be significant for Regeneron Pharmaceuticals. Positive results may enhance investor confidence and potentially boost the company’s stock performance. The study’s outcomes could also impact the competitive landscape in the treatment of follicular lymphoma, influencing other companies in the oncology sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.